Final-Program-ATS-2023-AP.vp

236

TUESDAY • MAY 23

P605 Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study/ M. Kraft, New York, NY P606 Tezepelumab Reduces Patient-reported Cough and Phlegm Production in Patients With Severe, Uncontrolled Asthma: Results From the Phase 3 NAVIGATOR Study/ M. Castro, Kansas City, KS P607 Biologic Responders and Super-responders in the International Severe Asthma Registry/ E. Denton, Melbourne, Australia P608 Demographic Characteristics of Patients Who Utilize Biologics for Severe Asthma: A Real-World European Perspective/ S. Valliant, Collegeville, PA P609 Blood Eosinophil and IgE Levels at Initiation of Biologics for the Treatment of Severe Asthma, a Perspective From US, EU-4, and UK/ S. Valliant, Collegeville, PA P610 Clinical Remission and Associated Reductions in Background Medication in Patients With Severe Asthma: An Analysis of the Phase 3b ANDHI in Practice Substudy/ T.W. Harrison, Cambridge, United Kingdom P611 Month-to-Month Real-World Patterns of Inhaler Use in Patients With Controlled and Uncontrolled Severe Asthma Treated With Biologics/ A. Mohan, Ann Arbor, MI Inflammation in Severe Asthma: A Comparison Between Phenotypes/ F. Ardesi, Varese, Italy P613 The Use of Biologics in a Real-world Setting Reduces Hospitalizations/ M. Mallozzi, Philadelphia, PA P614 Medication Adherence in Severe Asthma Patients Enrolling in the NHLBI Precise Study/ P. Akuthota, La Jolla, CA P615 Safety Signals on Parasitic Infections Related to Monoclonal Antibodies for Moderate-Severe Asthma Patients: Results from the Food and Drug Administration’s Adverse Event Reporting System/ V. Pera, Rotterdam, Netherlands P616 Patterns of Inhaler Use Associated With Short-term and Long-term Use of Biologics by Patients With Severe Asthma/ A. Boe, Parsippany, NJ P617 Clinical Remission in Oral Corticosteroid (OCS)-dependent Patients With Severe Asthma: An Analysis of the Andhi-IP and PONENTE Trials/ A. Menzies-Gow, London, United Kingdom P618 Association Between T2-related Comorbidities and Effectiveness of Biologics in Adult Patients From the International Severe Asthma Registry/ G. Scelo, Singapore, Singapore P612 Effects of Biologics on Systemic and Airway

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

C31

BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussionwith assigned facilitators.

P595 Long-term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: The Liberty Asthma Traverse Continuation Study/ J.F. Maspero, Buenos Aires, Argentina P596 Dupilumab Reduced Severe Exacerbation Rates and Improved Pre-bronchodilator Fev 1 in Patients With Moderate-to-Severe Asthma Regardless of Exacerbation History of ³ 1, ³ 2, or ³ 3 Prior Exacerbations: Liberty Asthma Traverse/ J.F. Maspero, Buenos Aires, Argentina P597 Real-world Effectiveness of Dupilumab in Biologic NaïVe Patients With Asthma: Analysis From the US Advantage Study/ R.H. Stanford, Chapel Hill, NC P598 Efficacy of Dupilumab in Patients With and Without a Minimally Important Reduction in Fractional Exhaled Nitric Oxide After 2 Weeks of Treatment/ I.D. Pavord, Oxford, United Kingdom P599 A Real-World Study to Evaluate the Effectiveness of Mepolizumab in Treating Severe Asthma in Taiwan (REMIT)/ X. Xu, Singapore, Singapore P600 The Influence of Administering Mepolizumab by Autoinjector on Real-world Outcomes in Severe Asthma: Results From the REALITI-A Study at 2 Years/ M.C. Liu, Baltimore, MD P601 Identifying Asthma Patients Eligible for Anti-IL5 Treatment Using Electronic Health Records/ F. Yang, Glasgow, United Kingdom P602 Approaching Clinical Remission in Severe Asthma: An Analysis of Patients With Comorbid Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Treated With Benralizumab Across Five Clinical Trials/ R.E. Louis, Liege, Belgium P603 Real-world Evidence of Benralizumab in Patients With Severe Eosinophilic Asthma and Nasal Polyps: Initial Results of the RANS Study/ T. Le, Gaithersburg, MD P604 Effect of Tezepelumab on Airway Hyperresponsiveness by Baseline Blood Eosinophil Count in Patients With Severe, Uncontrolled Asthma in the Phase 2 CASCADE Study/ C.E. Brightling, Leicester, United Kingdom

ATS 2023 • Washington, DC